查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976686

切片穿刺針市場：按針型、應用、針尖設計、應用領域、最終用戶和通路分類－2026-2032年全球預測

Biopsy Needles Market by Needle Type, Utility, Tip Design, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，切片穿刺針市場價值將達到 8.7047 億美元，到 2026 年將成長至 9.2252 億美元，到 2032 年將達到 13.3049 億美元，年複合成長率為 6.24%。

主要市場統計數據
基準年 2025 8.7047億美元
預計年份：2026年 9.2252億美元
預測年份 2032 1,330,490,000 美元
複合年成長率 (%) 6.24%

策略實施：為何切片穿刺針創新和籌資策略與不斷演變的診斷路徑、臨床工作流程以及醫療環境的轉型直接相關

切片穿刺針是現代診斷流程中不可或缺的組成部分，它使臨床醫生能夠以微創的方式收集組織樣本，並做出明確的臨床決策。過去十年，影像引導、針體設計和材料科學的不斷進步，拓展了經皮切片檢查技術的臨床應用範圍，使其涵蓋整個器官系統。隨著臨床流程向早期影像主導檢測和精準醫療方向發展，活體組織切片針本身已不再只是一個被動的器械，而是影響手術效率、安全性和後續診斷結果的關鍵因素。因此，製造商、臨床醫生和採購經理必須以綜合的方式評估產品的性能、手術適用性和生命週期經濟性。此外，醫療環境的變化，從住院病房到門診手術中心和診斷診所，正在改變設備的需求特徵和服務預期，促使製造商最佳化產品系列和商業策略。在此背景下，相關人員應優先考慮清晰了解手術要求、臨床醫生的工作流程以及設備特性與診斷結果之間的相互作用。透過這樣做，產品開發和商業化策略可以更恰當地與現代切片檢查實踐的運作實際情況以及臨床醫生、患者和醫療保健系統不斷變化的期望相一致。

診斷影像技術的整合、臨床環境的轉變以及監管和數位化需求的推動，正在對切片穿刺針的研發和採購進行重大變革。

切片穿刺針領域正經歷著一場變革，其驅動力包括技術創新、臨床實踐的改變以及對診斷準確性和患者體驗日益成長的期望。針體形狀、塗層和成像相容設計的進步，在減少取樣誤差和縮短手術時間的同時，也拓展了臨床醫師可進行的微創手術範圍。同時，真空抽吸系統的日益普及和影像導引平台的改進，正在重塑臨床醫生的選擇，使得在門診環境中進行更複雜的組織取樣成為可能。隨著醫療模式從住院轉向門診，人們對能夠快速安裝、一次性使用且無菌、庫存管理簡單的活體組織切片針的需求日益成長。同時，數位化整合也在不斷推進，手術數據採集、設備可追溯性以及與電子健康記錄的互通性，正成為系統級採購決策中的關鍵因素。監管機構對安全性和可追溯性的日益重視，不斷提高品質要求，而商業策略也越來越注重捆綁式產品、服務合約和培訓。因此，能夠將臨床證據的產生、可操作的治療方案和可擴展的生產相結合，以應對臨床醫生效率和醫療保健系統成本控制這兩大壓力的公司，正在獲得競爭優勢。

對 2025 年美國關稅變化對整個針頭價值鏈的影響進行全面分析，包括供應商選擇、製造決策、採購趨勢和供應鏈韌性。

美國於2025年實施的關稅調整的累積影響，已對整個切片穿刺針針價值鏈造成了顯著壓力，促使製造商和買家重新評估其採購、定價和庫存策略。對某些進口零件和組件徵收更高的關稅，推高了依賴跨境供應鏈的製造商的投入成本，尤其對金屬合金、精密加工零件和某些等級的聚合物影響尤為顯著。為此，許多供應商加快了在地採購和近岸外包的步伐，以降低貿易政策波動帶來的風險。同時，一些工程團隊探索了替代產品設計方案，透過改變零件分類來最大限度地減少關稅影響。醫院和門診機構透過審查採購合約和延長競標週期，確保在成本結構變化的情況下仍能持續供應。聯合採購組織也加強了談判，以維持價格的穩定性。同時，醫療設備製造商透過提高生產效率、自動化以及與供應商密切合作來降低成本，從而減輕了下游臨床採購部門的壓力。值得注意的是，這些調整措施因產品類型而異。與包含整合式電子元件和專有子組件的複雜可重複使用系統相比，材料清單清單 (BOM) 簡單的可重複使用產品更容易重新配置。展望未來，關稅主導的獎勵加速了供應商整合和區域投資決策，同時也強化了供應鏈透明度、多源採購和合約柔軟性對於切片穿刺針針生態系統中相關人員的重要性。

詳細的細分分析闡明了類型、處理方式、類別、材質、採購管道、應用和最終用戶等方面的差異對產品、定價和市場進入策略的影響。

細分市場層面的趨勢分析揭示了清晰的需求模式和策略重點，這些資訊可用於制定產品藍圖和進行商業性細分。按類型分類，單針活體組織切片針和Temno針在市場上有所區別，分別滿足臨床醫生不同的偏好和組織取樣技術。因此，設計最佳化和臨床醫生培訓對於在專業臨床環境中推廣應用至關重要。按操作流程分類，抽吸切片檢查、穿刺切片檢查和真空輔助切片檢查分別涉及不同的技術要求和臨床路徑。因此，器械開發商必須根據操作目的調整針頭形狀、管腔特性以及與輔助輔助器具的兼容性。按類別分類，一次性產品和可重複使用產品在經濟性和感染控制方面的影響各不相同，從而影響醫院和門診手術中心的採購決策。生命週期成本、滅菌通訊協定和監管因素決定了醫療機構是優先考慮一次性產品的便利性，還是更傾向於投資可重複使用產品。在基於材質的分類中，金屬和塑膠產品在剛度、影像偽影和製造成本方面各有優劣。因此，需要根據手術流程和臨床醫生的操作預期，謹慎選擇材質。在基於採購管道的分類中，隨著醫院和診所將傳統的直銷關係與電子採購和數位市場結合，線上線下銷售並存的趨勢日益明顯。這正在改變銷售模式和售後服務支援。就應用而言，乳房切片、腎臟切片檢查、肝臟活體組織切片、切片檢查切片檢查和前列腺切片檢查各自具有獨特的操作和取樣限制，從而決定了穿刺針的長度、切割機制以及與引導系統的兼容性。就最終用戶而言，門診手術中心、診斷診所和醫院各自優先考慮不同的性能特徵、服務水平和採購週期，因此，細分市場的商業化策略需要調整通訊、管道投資以及與臨床醫生的互動方式，以反映最終用戶的實際操作情況。

區域診斷和商業性特徵會影響產品適應性、監管方法、製造地和全球市場擴散模式。

區域趨勢對監管路徑、臨床實踐模式和生產策略產生顯著影響，從而帶來不同的機會和風險。在美洲，完善的臨床指南、影像導引手術的高普及率以及成熟的支付方環境，都為先進針頭設計和整合手術系統的快速推廣提供了支援。同時，上市後監管和醫療設備可追溯性在監管路徑中也受到重視。在歐洲、中東和非洲，監管環境的多樣性和報銷政策的波動，使得企業需要採取區域性的商業化策略，需要在集中核准、國家層面的市場進入規劃和有針對性的臨床證據生成之間取得平衡。在亞太地區，不斷擴展的診斷基礎設施、對本地生產的投資以及門診模式的快速普及正在推動市場成長，尤其是在對經濟高效的一次性產品和可擴展的培訓項目的需求方面。在所有地區，供應鏈結構和關稅風險各不相同，這會影響到組件採購、製造地和庫存策略等方面的決策。此外，不同地區對可重複使用解決方案和一次性解決方案的偏好，以及門診手術中心和獨立診斷診所的普及程度，都會影響產品的長期發展藍圖和服務模式。因此，企業應調整其研發、合規和商業化重點，以適應各地區的結構和臨床特徵，從而最大限度地提高產品的相關性和市場滲透率。

我們的公司和競爭對手分析揭示了成熟的製造商、專業創新者和策略聯盟如何推動其整個產品系列的差異化、普及和服務主導的客戶維繫。

切片穿刺針領域的競爭格局呈現出多元化的格局，既有成熟的醫療設備製造商，也有專注於創新領域的專業企業，還有新興的利基供應商。成熟的醫療設備製造商擁有廣泛的分銷網路、完善的綜合服務體係以及與臨床醫生建立的穩固關係，這使其能夠加速推廣漸進式創新。同時，專注於利基市場的企業則傾向於透過獨特的針頭形狀、新型材料以及針對特定手術的輔助器具來提升自身的技術競爭力。小規模的公司通常更注重臨床合作中的靈活性和客製化配置。各公司採取的策略性措施包括：透過有針對性的收購來拓展其手術產品組合；透過與影像和引導系統供應商合作提供捆綁式解決方案；以及投資於臨床證據以支持其性能對比聲明。售後服務（培訓、器械再處理支援和耗材供應合約）是重要的收入來源和客戶維繫，尤其是在手術量和臨床醫生偏好對市場影響顯著的情況下。此外，投資於模組化設計和互通介面的公司在與不同醫療機構的標準化醫療系統整合方面具有優勢。無論是新參與企業還是老牌企業，成功的企業都需要平衡臨床療效檢驗、供應鏈韌性和清晰的服務提案，以確保在醫院和門診處方清單上獲得永續的地位。

為製造商和買家提供具體的策略建議，以協調產品設計、供應鏈韌性、臨床證據開發和通路策略，從而確保永續的競爭力。

產業領導者應協調一系列策略行動，以贏得臨床青睞、應對成本壓力並提高供應可靠性。首先，應優先開發以臨床醫生為中心的產品，使針頭設計和操作相容性與已證實的臨床療效和易用性相匹配，從而實現醫院和門診的快速部署。其次，應透過多地點採購、盡可能選擇近岸外包以及強力的合約保障措施來增強供應鏈韌性，以減輕貿易政策和關稅波動的影響。同時，必須改善反映不斷變化的採購行為的商業模式，包括擴大電子採購系統的整合、加強數位化銷售支援以及為門診手術中心和診斷診所客製化產品。此外，還應建立強大的臨床證據項目，展示產品在常見應用領域的效能對比，並提供可擴展的培訓和支援服務，以減少操作差異。定價策略應柔軟性，對高效能設備採用基於價值的定價，並對大批量應用提供具有成本競爭力的耗材選項。最後，我們將促進與影像診斷和引導設備供應商的策略合作，儘早與支付方就報銷證據的需求進行溝通，並探索能夠快速響應臨床反饋和監管變化的模組化產品架構。透過全面實施這些措施，我們可以提高市場應對力，保障利潤率，並加強與醫療機構的關係。

除了對臨床醫生進行訪談、檢驗採購記錄以及審查監管和臨床文獻外，還採用了穩健的混合調查方法，透過三角測量法獲得了高度可靠的研究結果。

本研究途徑整合了結構化的初步研究（訪談對象包括臨床醫生、採購經理和行業高管）、對同行評審臨床文獻的系統性回顧以及對監管申報文件和醫療設備召回資料庫的分析。初步研究包括對介入放射科醫生、病理學家和手術全期護理師進行詳細訪談，以了解細微的手術操作細節、臨床醫生的偏好以及尚未解決的需求。與採購和供應鏈相關人員的對話，有助於深入了解競標趨勢、庫存管理實踐以及應對關稅波動導致的成本變化。二次研究涵蓋了醫療設備的技術規格、監管指南、臨床試驗註冊資訊和製造商產品文檔，以檢驗有關技術選擇和相容性的說法。採用數據三角測量法將質性研究結果與監管措施和臨床結果關聯起來，並使用分析框架整合供應鏈、監管和商業性影響。品質保證程序包括專家評審小組和臨床醫生的迭代檢驗，以確保研究結果的實用性和準確性。我們也明確記錄了局限性和注意事項，例如不同地區醫療保健模式的潛在差異，以及貿易和監​​管政策的演變性質，這些都可能隨著時間的推移改變商業性環境。

綜合經營團隊結論闡述了臨床、商業性和供應方面的因素如何匯聚並確定切片穿刺針針利益相關人員。

累積分析表明，切片穿刺針仍然是影響臨床表現、手術效率和供應鏈策略的關鍵環節。技術進步和醫療保健格局的變化重新定義了產品預期，而政策和貿易趨勢迫使製造商和買家重新調整籌資策略和成本管理方法。細分市場分析強調了針對特定手術流程的設計、針對通路量身定做的商業化以及以終端用戶為中心的服務模式的重要性。企業需要根據區域特性制定監管合規和市場准入計畫。在競爭激烈的環境中，能夠整合臨床驗證的、互通性的解決方案以及強大的生產基地的企業將獲得競爭優勢。隨著相關人員適應這些變化，最成功的機構將整合以臨床醫生主導的創新、嚴謹的供應鏈規劃以及能夠反映醫院系統和門診機構實際情況的靈活商業模式。這些基礎性措施將使企業和醫療保健系統能夠建立一個既能維持營運和財務穩定，又能改善診斷結果的系統。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：切片穿刺針市場－按針型分類

  • 核心針穿刺切片
    • 自動芯針
    • 半自動取芯針
    • 手動芯針
  • 穿刺輔助切片檢查
    • 乳房吸吮輔助針
    • 肺吸輔助針
  • 細針穿刺法
    • 常規細針穿刺法
    • 超音波引導下細針穿刺切片檢查
    • 經支氣管細針穿刺

第9章：切片穿刺針市場

  • 免洗針頭
  • 可重複使用的針頭

第10章：按針尖形狀分類的切片穿刺針市場

  • 斜刃
  • 鋸齒狀尖端
  • 側槽/窗口
  • 套管針

第11章：切片穿刺針市場：按應用領域分類

  • 乳房切片
  • 切片檢查
  • 肝臟切片檢查
  • 切片檢查
  • 攝護腺切片檢查

第12章：切片穿刺針市場：依最終用戶分類

  • 門診手術中心
  • 診斷診所
  • 醫院

第13章：切片穿刺針市場：按分銷管道分類

  • 離線
  • 線上

第14章：切片穿刺針市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：切片穿刺針市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：切片穿刺針市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國切片穿刺針市場

第18章：中國切片穿刺針市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Argon Medical Devices, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • Biomedical Srl
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Group Incorporated
  • Danaher Corporation
  • Doctor Japan Co., Ltd.
  • Dr. Japan Co. Ltd.
  • Freudenberg Medical, LLC
  • Fujifilm Holdings Corp
  • Geotek Medical
  • Hologic, Inc.
  • Inrad, Inc.
  • IZI Medical Products
  • Medax Srl
  • Medi-Tech Devices Pvt. Ltd.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Mermaid Medical Group
  • Olympus Corporation
  • Pajunk GmbH Medizintechnologie
  • Point Blank Medical
  • Remington Medical
  • Stryker Corporation
  • weLLgo Medical Products GmbH
Product Code: MRR-69324464D211

The Biopsy Needles Market was valued at USD 870.47 million in 2025 and is projected to grow to USD 922.52 million in 2026, with a CAGR of 6.24%, reaching USD 1,330.49 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 870.47 million
Estimated Year [2026] USD 922.52 million
Forecast Year [2032] USD 1,330.49 million
CAGR (%) 6.24%

Strategic introduction to why biopsy needle innovation and procurement align directly with evolving diagnostic pathways, clinical workflows and care setting transformation

Biopsy needles represent a foundational component of modern diagnostic pathways, enabling clinicians to obtain tissue with minimal invasiveness while informing definitive clinical decisions. Over the past decade, incremental advances in imaging guidance, needle design and materials science have expanded the clinical scope of percutaneous biopsy procedures across organ systems. As clinical pathways shift toward earlier, image-driven detection and precision medicine, the needle itself has become more than a passive instrument: it is a convergence point for procedural efficiency, safety, and downstream diagnostic yield. Consequently, manufacturers, clinicians and procurement leaders must evaluate product performance, procedural fit and lifecycle economics in tandem. Moreover, evolving care settings-from inpatient hospital suites to ambulatory surgical centers and diagnostic clinics-alter device demand profiles and service expectations, prompting manufacturers to refine portfolios and commercial approaches. In this context, stakeholders should prioritize a clear understanding of procedural requirements, clinician workflows and the interplay between device attributes and diagnostic outcomes. By doing so, product development and commercialization strategies can better align with the operational realities of contemporary biopsy practice and with the evolving expectations of clinicians, patients and health systems.

High-impact shifts redefining biopsy needle development and procurement driven by imaging integration, site-of-care migration, and regulatory and digital imperatives

The biopsy needle landscape is undergoing transformative shifts driven by technological innovation, changing site-of-care dynamics and heightened expectations for diagnostic accuracy and patient experience. Advancements in needle geometries, coatings and imaging-compatible designs are reducing sampling error and procedure time while expanding the range of minimally invasive interventions clinicians can perform. At the same time, broader adoption of vacuum-assisted systems and improvements in image-guidance platforms are reshaping clinician preferences and enabling more complex tissue sampling in outpatient settings. Shifting care from inpatient to ambulatory environments has prompted demand for needles optimized for rapid setup, single-use sterility and simplified inventory management. In parallel, digital integration is increasing: procedural data capture, device traceability and interoperability with electronic medical records are becoming differentiators for system-level purchasing decisions. Regulatory emphasis on safety and traceability continues to elevate quality requirements, while commercial strategies now place greater weight on bundled offerings, service contracts and training. As a result, the competitive playing field rewards firms that combine clinical evidence generation, practical procedural solutions and scalable manufacturing, enabling them to meet the simultaneous pressures of clinician efficacy and health system cost containment.

Comprehensive analysis of how United States 2025 tariff changes reshaped sourcing, manufacturing decisions, procurement dynamics, and supply chain resilience across the needle value chain

The cumulative implications of tariff adjustments instituted by the United States in 2025 have introduced measurable pressure across the biopsy needle value chain, prompting manufacturers and buyers to reassess sourcing, pricing and inventory strategies. Increased duties on certain imported components and subassemblies have elevated input costs for manufacturers that rely on cross-border supply networks, particularly for metal alloys, precision-machined parts and specific polymer grades. In response, many suppliers accelerated localization and nearshoring initiatives to reduce exposure to trade policy volatility, while some engineering teams explored product design alternatives to shift component classification and minimize tariff impact. Hospitals and ambulatory providers reacted by revisiting procurement contracts and extending tender cycles to secure supply continuity under changed cost structures, and group purchasing organizations intensified negotiations to retain predictable pricing. Simultaneously, device companies pursued cost containment through production efficiency, automation and closer vendor partnerships, which moderated downstream pressure on clinical purchasers. Importantly, these adaptations varied by product category: disposable items with simple bill-of-materials were easier to reconfigure than complex reusable systems with integrated electronics or proprietary subcomponents. Looking forward, tariff-driven incentives accelerated supplier consolidation and regional investment decisions, while also reinforcing the importance of supply chain transparency, multi-origin sourcing and contractual flexibility for stakeholders across the biopsy needle ecosystem.

In-depth segmentation insight clarifying how type, procedure, category, material, purchasing channel, application and end-user distinctions shape product, pricing and go-to-market choices

Segment-level dynamics reveal distinct demand patterns and strategic priorities that should inform product roadmaps and commercial segmentation. Based on Type, the market differentiates between monopty needle and temno needle, each serving unique clinician preferences and tissue-sampling techniques; design optimization and clinician training are therefore critical for adoption within specialty practices. Based on Procedure, aspiration biopsy, core biopsy and vacuum-assisted biopsy follow different technical requirements and clinical pathways, so device developers must match needle geometry, inner lumen characteristics and compatibility with procedural accessories to procedural intent. Based on Category, disposable and reusable options carry divergent economic and infection-control implications, which impacts purchasing decisions by hospitals and ambulatory surgical centers; lifecycle costs, sterilization protocols and regulatory requirements influence whether institutions favor single-use convenience or reusable capital investments. Based on Material, metal and plastic constructions offer trade-offs in rigidity, imaging artifact and manufacturing cost, requiring careful material selection aligned to procedural contexts and clinician handling expectations. Based on Purchasing Channel, offline sales and online sales increasingly coexist as hospitals and clinics blend traditional direct sales relationships with eProcurement and digital marketplaces, changing salesforce models and aftersales support. Based on Application, breast biopsy, kidney biopsy, liver biopsy, lung biopsy and prostate biopsy each impose specific access and sampling constraints, shaping needle length, cutting mechanisms and compatibility with guidance systems. Based on End User, ambulatory surgical centers, diagnostic clinics and hospitals prioritize different performance attributes, service levels and procurement cycles, so segmentation-aware commercialization strategies must adapt messaging, channel investment and clinician engagement to reflect end-user operational realities.

Regional diagnostic and commercial nuances that influence product adaptation, regulatory approach, manufacturing footprints and adoption patterns across global markets

Regional dynamics exert meaningful influence on regulatory pathways, clinician practice patterns and manufacturing strategies, producing differentiated opportunities and risks. In the Americas, established clinical guidelines, high adoption of image-guided procedures and a well-developed payer environment support rapid uptake of advanced needle designs and integrated procedural systems, while regulatory pathways emphasize post-market surveillance and device traceability. In Europe, Middle East & Africa, regulatory diversity and variable reimbursement landscapes mean commercialization approaches must be regionally tailored, balancing centralized approvals with country-level market access planning and targeted clinical evidence generation. In Asia-Pacific, growth is being driven by expanding diagnostic infrastructure, investments in local manufacturing and rapid adoption in outpatient care models, with particular demand for cost-efficient disposables and scalable training programs. Across all regions, supply chain configurations and tariff exposures differ, influencing decisions about component sourcing, manufacturing location and inventory strategy. Additionally, regional preferences for reusable versus disposable solutions and the penetration of ambulatory surgical centers versus standalone diagnostic clinics shape long-term product roadmaps and service models. Consequently, companies should align R&D, regulatory and commercial priorities with the specific structural and clinical characteristics of each region to maximize relevance and uptake.

Corporate and competitive analysis revealing how legacy manufacturers, focused innovators and strategic partnerships drive differentiation, adoption and service-led retention across product portfolios

Competitive dynamics in the biopsy needle arena reflect a mix of legacy device manufacturers, specialized innovators and emerging niche suppliers. Established medical device manufacturers maintain broad distribution networks, integrated services and established clinician relationships that can accelerate adoption of incremental innovations. Conversely, focused niche players often drive technical differentiation through proprietary needle geometries, novel materials and procedure-specific adjuncts, while smaller firms typically emphasize agility in clinical collaboration and custom configurations. Strategic behaviors observed across companies include targeted acquisitions to augment procedural portfolios, partnerships with imaging and guidance system providers to deliver bundled solutions, and investments in clinical evidence to support comparative performance claims. Aftermarket services-training, instrument reprocessing support and consumable supply agreements-have become important revenue and retention levers, particularly in settings where procedure volume and clinician preference exert heavy influence. Moreover, companies that invest in modular designs and interoperable interfaces have an advantage when engaging health systems seeking to standardize across multiple sites of care. For market entrants and incumbents alike, successful players will balance clinical validation, supply chain robustness and a clear service proposition to secure durable placement in hospital and outpatient formularies.

Actionable strategic recommendations for manufacturers and purchasers to align product design, supply chain resilience, clinical evidence development and channel strategies for sustained competitiveness

Industry leaders should pursue a coordinated set of strategic actions to capture clinical preference, manage cost pressure and strengthen supply reliability. First, prioritize clinician-centered product development that aligns needle design and procedure compatibility with documented clinical outcomes and ease-of-use, enabling faster uptake in both hospital and outpatient settings. Next, invest in supply chain resilience through multi-origin sourcing, nearshoring where feasible and stronger contractual protections to mitigate trade-policy and tariff volatility. Simultaneously, refine commercial models to reflect evolving purchasing behaviors by expanding eProcurement integration, enhancing digital sales enablement and tailoring offerings for ambulatory surgical centers and diagnostic clinics. Additionally, build robust clinical-evidence programs that demonstrate comparative performance across commonly performed applications, while also creating scalable training and support services to reduce procedural variability. Pricing strategies should be flexible, incorporating value-based pricing for high-performance devices and cost-competitive disposable options for volume-driven applications. Finally, pursue strategic partnerships with imaging and guidance vendors, engage with payers early on reimbursement evidence needs, and consider modular product architectures to respond rapidly to clinical feedback and regulatory changes. Together, these measures will improve market responsiveness, protect margins and strengthen institutional relationships.

Robust mixed-methods research approach combining clinician interviews, procurement validation, regulatory and clinical literature review plus triangulation for high-integrity insights

The research approach combined structured primary engagement with clinicians, procurement leads and industry executives, systematic review of peer-reviewed clinical literature and analysis of regulatory filings and device recall databases. Primary inputs included in-depth interviews with interventional radiologists, pathologists and perioperative nurses to capture procedural nuances, clinician preferences and unmet needs. Procurement and supply chain conversations provided insight into tender dynamics, inventory practices and responses to tariff-driven cost changes. Secondary research encompassed technical device specifications, guidance from regulatory agencies, clinical trial registries and manufacturer product literature to validate engineering choices and compatibility claims. Data triangulation methods were applied to cross-check qualitative insights against regulatory actions and clinical outcomes, and analytic frameworks were used to synthesize supply chain, regulatory and commercial implications. Quality assurance steps included expert review panels and iterative validation with practicing clinicians to ensure practical relevance and accuracy. Limitations and caveats were explicitly documented, including potential variability across local practice patterns and the evolving nature of trade and regulatory policy that may alter commercial conditions over time.

Executive conclusion synthesizing how clinical, commercial and supply-side forces converge to define strategic priorities for biopsy needle stakeholders

The cumulative analysis underscores that biopsy needles remain a critical intersection of clinical performance, procedural efficiency and supply chain strategy. Technological progress and shifting care settings are redefining product expectations, while policy and trade developments are compelling manufacturers and purchasers to reprioritize sourcing and cost-management tactics. Segmentation insights highlight the need for procedure-specific design, channel-tailored commercialization and end-user-aware service models. Regional nuances demand customized regulatory and market access planning, and competitive dynamics reward firms that combine clinical evidence, interoperable solutions and resilient manufacturing footprints. As stakeholders navigate these changes, the most successful organizations will integrate clinician-led innovation, disciplined supply chain planning and flexible commercial models that reflect the realities of both hospital systems and outpatient providers. These foundational actions will position companies and health systems to improve diagnostic outcomes while maintaining operational and financial stability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Needles Market, by Needle Type

  • 8.1. Core Needle Biopsy
    • 8.1.1. Automatic Core Needles
    • 8.1.2. Semi-Automatic Core Needles
    • 8.1.3. Manual Core Needles
  • 8.2. Vacuum-Assisted Biopsy
    • 8.2.1. Breast Vacuum-Assisted Needles
    • 8.2.2. Lung Vacuum-Assisted Needles
  • 8.3. Fine Needle Aspiration
    • 8.3.1. Conventional Fine Needle Aspiration
    • 8.3.2. Endoscopic Ultrasound-Guided Fine Needle Aspiration
    • 8.3.3. Transbronchial Fine Needle Aspiration

9. Biopsy Needles Market, by Utility

  • 9.1. Disposable Needles
  • 9.2. Reusable Needles

10. Biopsy Needles Market, by Tip Design

  • 10.1. Beveled
  • 10.2. Serrated Tip
  • 10.3. Side-Slot/Window
  • 10.4. Trocar Tip

11. Biopsy Needles Market, by Application

  • 11.1. Breast Biopsy
  • 11.2. Kidney Biopsy
  • 11.3. Liver Biopsy
  • 11.4. Lung Biopsy
  • 11.5. Prostate Biopsy

12. Biopsy Needles Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Clinics
  • 12.3. Hospitals

13. Biopsy Needles Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Biopsy Needles Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biopsy Needles Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biopsy Needles Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biopsy Needles Market

18. China Biopsy Needles Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Argon Medical Devices, Inc.
  • 19.6. B. Braun SE
  • 19.7. Becton, Dickinson and Company
  • 19.8. Biomedical Srl
  • 19.9. Boston Scientific Corporation
  • 19.10. Cardinal Health, Inc.
  • 19.11. Cook Group Incorporated
  • 19.12. Danaher Corporation
  • 19.13. Doctor Japan Co., Ltd.
  • 19.14. Dr. Japan Co. Ltd.
  • 19.15. Freudenberg Medical, LLC
  • 19.16. Fujifilm Holdings Corp
  • 19.17. Geotek Medical
  • 19.18. Hologic, Inc.
  • 19.19. Inrad, Inc.
  • 19.20. IZI Medical Products
  • 19.21. Medax Srl
  • 19.22. Medi-Tech Devices Pvt. Ltd.
  • 19.23. Medtronic PLC
  • 19.24. Merit Medical Systems, Inc.
  • 19.25. Mermaid Medical Group
  • 19.26. Olympus Corporation
  • 19.27. Pajunk GmbH Medizintechnologie
  • 19.28. Point Blank Medical
  • 19.29. Remington Medical
  • 19.30. Stryker Corporation
  • 19.31. weLLgo Medical Products GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY NEEDLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY NEEDLES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPSY NEEDLES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIOPSY NEEDLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIOPSY NEEDLES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPSY NEEDLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY AUTOMATIC CORE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY AUTOMATIC CORE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY AUTOMATIC CORE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SEMI-AUTOMATIC CORE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SEMI-AUTOMATIC CORE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SEMI-AUTOMATIC CORE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY MANUAL CORE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY MANUAL CORE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY MANUAL CORE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BREAST VACUUM-ASSISTED NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BREAST VACUUM-ASSISTED NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BREAST VACUUM-ASSISTED NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LUNG VACUUM-ASSISTED NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LUNG VACUUM-ASSISTED NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LUNG VACUUM-ASSISTED NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CONVENTIONAL FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CONVENTIONAL FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY CONVENTIONAL FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TRANSBRONCHIAL FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TRANSBRONCHIAL FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TRANSBRONCHIAL FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DISPOSABLE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DISPOSABLE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DISPOSABLE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REUSABLE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REUSABLE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REUSABLE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BEVELED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BEVELED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BEVELED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SERRATED TIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SERRATED TIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SERRATED TIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SIDE-SLOT/WINDOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SIDE-SLOT/WINDOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY SIDE-SLOT/WINDOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TROCAR TIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TROCAR TIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY TROCAR TIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BREAST BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BREAST BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY BREAST BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY KIDNEY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY KIDNEY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LIVER BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LIVER BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LIVER BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LUNG BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LUNG BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY LUNG BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY PROSTATE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY PROSTATE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY PROSTATE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DIAGNOSTIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DIAGNOSTIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DIAGNOSTIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 231. NATO BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BIOPSY NEEDLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BIOPSY NEEDLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BIOPSY NEEDLES MARKET SIZE, BY NEEDLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BIOPSY NEEDLES MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BIOPSY NEEDLES MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BIOPSY NEEDLES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA BIOPSY NEEDLES MARKET SIZE, BY UTILITY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA BIOPSY NEEDLES MARKET SIZE, BY TIP DESIGN, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA BIOPSY NEEDLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA BIOPSY NEEDLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA BIOPSY NEEDLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)